Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Total search results: 10455 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 103 104 105  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases 2019-02-07
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker Corp–Genedata: drug screening software, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Lilly–ProteoNic: rec protein production technology, 201902– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-02-05
Roche–Xencor: cancer immunotherapy, 201901– collab developm + commerc ww $120m upfront + milestones + profit share IL-15 cytokine drugs Genentech 2019-02-05
Argen-X–Halozyme: drug delivery technology, 201901– collab + license agreem ww for Enhanze technology $30m upfront + milestones + royalties 2019-02-04
Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot 2019-02-04
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners 2019-02-01
Axial Biotherapeutics–SEVERAL: investment, 201902 financing round Series B $25m incl Seventure Partners 2019-02-01
ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED 2019-01-31
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
Bayer–Univ Kyoto: drug discovery, 201901– collab €na research alliance for drug target discovery for pulmonary diseases incl IPF 2019-01-31
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Dewpoint Therapeutics–6 Dimensions Capital: investment, 201901 financing round Series A totallling $60m incl co-investor 6 Dimensions Capital 2019-01-30
Dewpoint Therapeutics–Alexandria Real Estate: investment, 201901 financing round Series A totallling $60m incl co-investor Alexandria Ventures 2019-01-30
Dewpoint Therapeutics–Bayer: investment, 201901 financing round Series A totallling $60m incl co-investor Leaps by Bayer 2019-01-30
Dewpoint Therapeutics–EcoR1 Capital: investment, 201901 financing round Series A totallling $60m incl co-investor EcoR1 Capital 2019-01-30
Dewpoint Therapeutics–Polaris Partners: investment, 201901 financing round Series A totallling $60m incl lead investor Polaris Partners 2019-01-30
Dewpoint Therapeutics–Samsara BioCapital: investment, 201901 financing round Series A totallling $60m incl co-investor Samsara BioCapital 2019-01-30
Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners 2019-01-30
Labcyte–Danaher: investment, 201901 acquisition of Labcyte by Beckman Coulter Life Sciences 2019-01-30
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Medizinsches Labor Hannover–Labor Limbach: investment, 201901 acquisition 100% of MLH by Limbach Gruppe SE PENDING 2019-01-26
Biocartis–SEVERAL: investment, 201901 private placement €55.5m of 5m new shares at €11.1/share 2019-01-23
Grifols–Rigel: fostamatinib, 201901– collab + license $30m upront + $297.5m milestones + royalties all indications in Europe + Turkey 2019-01-23
MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health 2019-01-21
Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel 2019-01-21
ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models 2019-01-17
ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging 2019-01-17
Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy 2019-01-17
Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders 2019-01-17
Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH 2019-01-16
Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF 2019-01-16
Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH 2019-01-16
Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains 2019-01-16
Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. 2019-01-16
Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR 2019-01-16
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins 2019-01-15
InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures 2019-01-15
InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere 2019-01-15
InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere 2019-01-15
Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies 2019-01-15
Alnylam–SEVERAL: investment, 201901 public offering $387.5m with 5m shares common stock at $77.5/share 2019-01-14
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux 2019-01-14
Merck (DE)–Roche: biochemical reagents, 201901–2025 distribution extension ww excl of Roche biochemical reagents portfolio 2019-01-14
Solentim–Sciad Communications: public relations, 201901 service existent by Sciad 2019-01-14
Affimed–JPMorgan Chase: investor conference, 201901 supply service Affimed presents at JP Morgan Healthcare Conference 2019 2019-01-10
Chronomics–SEVERAL: investment, 201901 seed financing round £1.12m from Anthemis + SOSV 2019-01-10
Evotec–JPMorgan Chase: investor conference, 201901 supply service Evotec presents at JP Morgan Healthcare Conference 2019 2019-01-10
Samplix–EU (govt): grant, 201901– Horizon 2020 SME Instrument Program Grant €1.9m 2019-01-10
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
UroGen–JPMorgan Chase: investor conference, 201901 supply service UroGen Pharma presents at JP Morgan Healthcare Conference 2019 2019-01-10
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB 2019-01-09
Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019 2019-01-09
Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 2019-01-09
Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences 2019-01-09
CureVac–Global Health PR: public relations, 201809 service existent media relations by Global Health PR 2019-01-08
AstraZeneca–Aptamer Group: aptamer drug conjugates, 201901– collab research to enable drug delivery to the kidney 2019-01-07
Bruker Corp–JPMorgan Chase: investor conference, 201901 supply service Bruker presents at JP Morgan Healthcare Conference 2019 2019-01-07
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Keros Therapeutics–SEVERAL: investment, 201901 financing round Series B $23m incl Pontifax + Arkin Bioventures + Partners Innovation Fund 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield Management: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
next pagenext page 1 2 3 ... 103 104 105  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top